Source comparison
Thymosin Alpha-1: Peptide Comparison
Researchers frequently compare thymosin alpha-1 to other immunomodulatory peptides when designing immune function studies. The table below contrasts thymosin alpha-1 with related research peptides across mechanism, half-life, primary research applications, and
This comparison does not assign a generated winner or score.
- Researchers frequently compare thymosin alpha-1 to other immunomodulatory peptides when designing immune function studies. The table below contrasts thymosin alpha-1 with related research peptides across mechanism, half-life, primary research applications, and practical handling considerations.
- Thymosin Alpha-1
- TLR9 agonist; enhances T-cell differentiation and IL-2 production
- 2–3 hours (human)
- Immune dysfunction, sepsis models, hepatitis research, cancer immunotherapy adjuvant
- 28 days at 2–8°C in bacteriostatic water
- Best choice for T-cell modulation studies; limited effect on humoral immunity; well-characterized safety profile
- Thymalin
- Thymic polypeptide fraction; broad immune regulation
- 4–6 hours
- Immunosenescence research, thymic function restoration
- 21 days at 2–8°C; more temperature-sensitive than thymosin alpha-1
- Broader immune effects but less mechanistic specificity; useful for aging immunity models
- TB 500 (Thymosin Beta-4)
- Actin-binding protein; promotes cell migration and angiogenesis
- 2 hours
- Wound healing, tissue repair, cardiovascular research
- 28 days at 2–8°C; stable across pH 5.5–7.5
- Structurally related to thymosin alpha-1 but functionally distinct; minimal immune modulation effects
- ARA 290
- Innate repair receptor agonist; anti-inflammatory signaling
- 4–5 hours
- Neuroprotection, inflammatory pain models, tissue injury
- 14 days at 2–8°C; freeze-thaw sensitive
- Complements thymosin alpha-1 in multi-pathway immune studies; focus on innate vs adaptive immunity
- The comparison clarifies why thymosin alpha-1 remains the preferred peptide for T-cell-specific research: its mechanism is well-defined at the receptor level (TLR9), its stability profile allows for longer experimental timelines, and decades of published research provide mechanistic benchmarks. TB 500 shares a naming similarity but addresses entirely different biological processes. Actin dynamics rather than immune signaling. ARA 290 offers complementary innate immune modulation but with shorter reconstituted stability, making it less suitable for multi-week studies.